In 2023, the global Primary Sclerosing Cholangitis (PSC) market is expected to be worth US$ 151.07 million. The overall demand for Primary Sclerosing Cholangitis (PSC) is expected to grow at a CAGR of 7.6% between 2023 and 2033, totaling around US$ 314.26 Million by 2033, owing to rising alcohol consumption.
According to Future Market Insights, the Primary Sclerosing Cholangitis (PSC) market is expected to grow during the analysis period, owing to factors such as an increase in the incidence of liver diseases and an increase in alcohol consumption. According to the Centers for Disease Control and Prevention, the global incidence of liver disease in 2016 was 3.9 million. According to the World Health Organization (WHO), the prevalence of liver cirrhosis is increasing in European countries due to high alcohol consumption. Additionally, rising awareness programmes and an increase in R&D investment for the development of new drug molecules are expected to boost the growth of the primary sclerosing cholangitis market during the forecast period.
Get Sample PDF of the Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16176
COVID-19 Impact Analysis on Primary Sclerosing Cholangitis (PSC) Market
The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Primary Sclerosing Cholangitis (PSC) market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Primary Sclerosing Cholangitis (PSC) market.
Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.
The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Primary Sclerosing Cholangitis (PSC) market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.
Why Choose Future Market Insights
- Serving domestic and international clients 24/7
- Prompt and efficient customer service
- Data collected from reliable primary and secondary sources
- Highly trained and experienced team of research analysts
- Seamless delivery of tailor-made market research reports
Discounted prices for new customers! Offer expires soon!
Get in Touch With Our Team For Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16176
Primary Sclerosing Cholangitis (PSC) Market: Segmentation
Valuable information covered in the FMI’s Primary Sclerosing Cholangitis (PSC) market report has been segregated into key segments and sub-segments.
Primary Sclerosing Cholangitis (PSC) Market by Drug:
- BTT1023
- GS-9674
- NGM282
- OCA
- Cenicriviroc
- LUM001
- DUR928
- norUDCA
- HTD1801
- IDN-7314
- STP705
Primary Sclerosing Cholangitis (PSC) Market: Competition Analysis
The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Primary Sclerosing Cholangitis (PSC) market. Competitive information detailed in the Primary Sclerosing Cholangitis (PSC) market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Primary Sclerosing Cholangitis (PSC) market report.
Key players covered in the report include:
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd
Important Questions Answered in the Primary Sclerosing Cholangitis (PSC) Market Report
- Which end user remains the top revenue contributor in different regional markets?
- At what rate has the global Primary Sclerosing Cholangitis (PSC) market been expanding during the forecast period?
- How will the global Primary Sclerosing Cholangitis (PSC) market look like by the end of the forecast period?
- What innovative strategies are adopted by Primary Sclerosing Cholangitis (PSC) market players to stay ahead of the pack?
- What are the restraints affecting the growth of the global Primary Sclerosing Cholangitis (PSC) market?
Visit for Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16176
Key Offerings of the Report
- Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
- Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
- Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
- Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with necessary information to take critical decisions
- Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Primary Sclerosing Cholangitis (PSC) market
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
